Ancient herbs meet modern medicine: can Curcumin-QingDai tame UC?

NCT ID NCT07665294

Not yet recruiting Disease control Sponsor: Ryan C Ungaro Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 2 times

Summary

This study tests whether adding a combination of curcumin (from turmeric) and QingDai (a traditional Chinese herb) to standard vedolizumab treatment can help people with moderate to severe ulcerative colitis reach remission. About 160 adults will receive either the herbal combo or a placebo, alongside their usual vedolizumab. The main goal is to see if more people achieve symptom-free remission after 12 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Curcumin-QingDai (CurQD) capsules
What this could lead to: If it works, this could point toward a safe, plant-based add-on therapy to help more people with ulcerative colitis achieve remission without stronger drugs.
What could go wrong: This is a relatively small Phase 4 trial testing a supplement combination, so results may not be definitive. The placebo effect in UC trials is often high, and QingDai has been linked to rare but serious lung and liver issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ULCERATIVE COLITIS

Contacts and locations

Locations

Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.